ClinicalTrials.gg
RecruitingNCT07363057GIANTS-1Updated Jan 26, 2026

A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer Survivors

A Phase 2 interventional study of GI-102 in combination with GIB-7 and Placebo in Cancer Survivors, Healthy Participant and Elderly, sponsored by GI Innovation, Inc.. Recruiting at 2 sites in Australia. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by GI Innovation, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This Phase 2a clinical study (GIANTS-1) aims to evaluate a novel dual-combination strategy using GI-102 and GIB-7 to address key pathological features of aging, including immunosenescence (the aging of the immune system), metabolic dysfunction, and gut-brain-muscle axis dysregulation.

Read the detailed description

GI-102 targets immunosenescence and inflammation: GI-102 is a bispecific immunocytokine composed of CD80 fused with a mutated interleukin (IL)-2. It is currently being evaluated in an ongoing Phase 2 oncology study, in which its safety and tolerability has been evaluated. Clinically meaningful biological activity-such as increased peripheral lymphocyte counts (including CD8+ T cells and natural killer [NK] cells)-has been observed, supporting its potential role in immune reactivation and inflammation modulation in the aging population.

GIB-7 restores gut-brain-muscle axis and circadian rhythm: GIB-7 is a proprietary synbiotic formulation that contains four probiotic strains- Limosilactobacillus fermentum, Lactiplantibacillus plantarum, which are gram-positive lactic acid bacteria. Additionally, it contains the strains Lactobacillus acidophilus, and Bifidobacterium animalis subsp. lactis. These components collectively support gut microbial stability and systemic physiological balance. In a clinical study conducted in healthy older adults (NCT05735418), GIB-7 demonstrated significant improvements in grip strength and reductions in inflammatory markers, with no investigational product (IP)-related adverse events (AEs), confirming its excellent safety profile. Additionally, GIB-7 has been shown to support circadian rhythm regulation, a key aspect of homeostatic aging that is often disrupted in older adults.

The rationale for combining these two agents is their complementary mechanisms:

  • GI-102 aims to remove senescent cells and thereby reduce inflammaging (a form of low-grade inflammation associated with ageing) via immune reactivation.
  • GIB-7 aims to enhance gut stability and support the gut-brain-muscle axis and circadian alignment, thereby improving physical and cognitive resilience.

This dual-combination strategy addresses complementary hallmarks of aging, offering a mechanistically integrated approach to extending healthspan (the period during which individuals remain functional and free of chronic diseases) in healthy adults and cancer survivors.

02

Conditions studied

  • Cancer Survivors
  • Healthy Participant
  • Elderly

Keywords

  • GI-102
  • GIB-7
  • aging
  • immunosenescence
  • gut-brain-muscle axis dysregulation
  • metabolic dysfunction
03

In context

Lead sponsor

GI Innovation, Inc. is the lead sponsor of 5 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. Must be aged between ≥18 and ≤80 years old at the time of .
  2. At the discretion of the Investigator, must be in a state of general health that is not severely compromised (ie, no life-threatening illness or disability).
  3. Participants with a history of cancer may be included only if they meet one of the following:

    1. Participants have been disease-free for ≥2 years; OR
    2. For those diagnosed within 2 years:

      • The cancer was treated with curative intent (eg, surgery, anti-cancer agents including chemotherapy)
      • Participants have been in remission for ≥12 months
      • Participants are not on any active cancer treatment except maintenance therapies (eg, endocrine therapy or bisphosphonates)
      • Participants must have received systemic anti-cancer therapies without immunotherapy for their cancers
  4. Women of (WOCBP; see definition in Section 5.3) must agree to use a highly effective method of from 14 days prior to Visit 2 until 180 days after the last dose of study medication (GI-102 or GIB-7). Fertile men must agree to use an acceptable method of contraception from 14 days prior to Visit 2 until 90 days after the last dose of study medication (GI-102 or GIB-7).

Key Exclusion Criteria:

  1. Severe and poorly managed chronic diseases, such as advanced cardiovascular disease, kidney failure requiring transplant or dialysis, uncontrolled diabetes, detectable (≤ 2 years), severe (COPD), or untreatable, terminal cancer as judged by the Investigator or history of life threatening infection (eg, meningitis).
  2. Dependent on walkers or wheelchairs; severe difficulty or inability to perform activities of daily living independently or inability to perform study measures required to test muscle function (an amputee is eligible if participants can walk without walkers or wheelchair) as judged by the Investigator.
  3. Major surgery within the past 6 months or scheduled during the study period, including severe orthopedic diseases requiring joint replacement surgery.
  4. History of substance abuse or dependency or history of recreational IV drug use over the last 5 years (by self-declaration).
  5. Female participants who are pregnant, planning to become pregnant, or breastfeeding during the study period. Participants undergoing perimenopause or the menopause transition are eligible.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
15 participants (estimated)

Study arms

  • Active comparator
    Part A

    GI-102 in combination with GIB-7

    Combination Product: GI-102 in combination with GIB-7

  • Active comparator
    Part B Arm 1

    GI-102 in combination with GIB-7

    Combination Product: GI-102 in combination with GIB-7

  • Placebo comparator
    Part B Arm 2

    Placebo for GI-102 in combination with GIB-7

    Combination Product: Placebo

Interventions

  • Combination productGI-102 in combination with GIB-7

    Drug page: Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102

    GI-102: recombinant protein drug, intravenous (IV) infusion, once every 4 weeks (Q4W); GIB-7: synbiotic formula, oral administration, once daily (QD)

    Also known as: efzilonkofusp alfa in combination with GIB-7

  • Combination productPlacebo

    Placebo for GI-102 in combination with GIB-7

06

What researchers measure

Primary outcomes

  1. Change in Baseline values in immune response (NK cells) before and after GI-102 and GIB-7 combination treatment

    Maximum change from Baseline values in immune function, primarily in natural killer (NK) cells assessed by flow cytometry in blood samples.

    Time frame: From Day 1 until Week 10 visit

  2. Change in Baseline values in immune response (CD8+ T cells) before and after GI-102 and GIB-7 combination treatment

    Maximum change from Baseline values in immune function, primarily in CD8⁺ T cells assessed by flow cytometry in blood samples.

    Time frame: From Day 1 until Week 10 visit

  3. Frequency of Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) of the combination of GI-102 and GIB-7 by severity

    Frequency of Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) by severity.

    Time frame: From Day 1 until Week 10 visit

  4. Number of participants with various adverse events and abnormal lab data

    Number of participants with Treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), abnormal Vital signs, abnormal Electrocardiograms (ECGs), abnormal Physical examination findings, abnormal Chest X-ray, or abnormal Laboratory tests results

    Time frame: From Day 1 until Week 10 visit

Secondary outcomes

  1. Change in Baseline values in sleep quality before and after GI-102 and GIB-7 combination treatment

    Change from Baseline values in sleep quality using ISI (Insomnia Severity Index) at Week 8 and Week 10

    Time frame: From Day 1 until Week 10 visit

  2. Change in Baseline values in quality of life before and after GI-102 and GIB-7 combination treatment

    Change from Baseline values in quality of life using EQ-5D (EuroQol 5 Dimension) at Week 8 and Week 10

    Time frame: From Day 1 until Week 10 visit

  3. Change in Baseline values in muscle function (hand grip strength) before and after GI-102 and GIB-7 combination treatment

    Change from Baseline values in muscle function using hand grip strength test at Week 8 and Week 10

    Time frame: From enrollment to the end of study

  4. Change in Baseline values in muscle function (6 minute walk test) before and after GI-102 and GIB-7 combination treatment

    Change from Baseline values in muscle function using 6 minute walk test at Week 8 and Week 10

    Time frame: From enrollment to the end of study

Other outcomes

  1. Change in Baseline values in the hospital visits by GI-102 and GIB-7 combination treatment

    Number of hospital visits compared to placebo at Week 8 and Week 10 (falls, fractures, pneumonia or severe respiratory illness, and other major health events may also be collected) to be conducted in a subgroup analysis (≥ 50 years)

    Time frame: From Day 1 until Week 10 visit

  2. Change in Baseline values in gut microbiome by GI-102 and GIB-7 combination treatment

    Change from Baseline values in gut microbiome at Week 8 and Week 10 as indicated by fecal microbiota changes using alpha-diversity values and taxonomic relative abundances.

    Time frame: From Day 1 until Week 10 visit

  3. Change in Baseline values in cognitive function by GI-102 and GIB-7 combination treatment

    Change from Baseline values in cognitive function at Week 8 and Week 10 as assessed by MoCA (Montreal Cognitive Assessment)

    Time frame: From Day 1 until Week 10 visit

  4. Survival (cancer survivors only)

    In this study investigators will monitor overall survival defined as time from the inclusion to death or end of follow up at Week 10 (whichever comes first).

    Time frame: From Day 1 until Week 10 visit

  5. Recurrence (cancer survivors only)

    In this study investigators will monitor cancer recurrence defined as time from the inclusion to the first recurrence or end of follow up at Week 10 (whichever comes first).

    Time frame: From Day 1 until Week 10 visit

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data and biospecimens collected in this study may be accessed by the XPRIZE Foundation and its designated Judging Panel solely for the purpose of verifying study results and evaluating eligibility for the XPRIZE Healthspan Competition. No identifiable personal information will be shared, and all data provided will remain confidential and used only for competition judging and audit purposes.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for May 2026, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Jan 23, 2026
StartEst.
Jan 2026
Primary completionEst.
May 2026
CompletionEst.
Oct 1, 2026
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07363057
Lead sponsor
GI Innovation, Inc.
Collaborators
GILongevity
Responsible party
Sponsor
First posted
Jan 23, 2026
Start date
Jan 2026 (estimated)
Primary completion
May 2026 (estimated)
Completion
Oct 1, 2026 (estimated)
Last update
Jan 26, 2026

Study contacts

Wayne Lee, Ph.D., MBA
Contact
woohyung.wayne.lee@gi-innovation.com
+82-2-404-2003
Karen Hwang
Contact
+82-2-404-2003

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102

Start the discussion